Bristol-Myers Squibb Waiting Period Over in ZymoGenetics Acquisition

1,363 views
  • About
  • Add to
Bristol-Myers Squib (BMY) said today that the Hart-Scott-Rodino waiting period for its offer to acquire ZymoGenetics (ZGEN) has expired. Bristol-Myers initiated its $9.75 per share cash tender offer for ZymoGenetics on September 10.

0 comments